NeuroFx, Inc.

Biotech · Private

Thera-101, a regenerative medicine therapeutic derived from adult adipose-derived stem cell secretome factors for treating stress urinary incontinence

Grants
$238K
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
3
2 granted · 1 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Mitigation of Acute and Chronic Kidney Injuries by Systemic Infusion of Adipose-Derived Soluble Therapeutic Factor Concentrate$238,130
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
3257ADVANCED RNA TECHNOLOGIES, LLC——
3258RESEARCH AND DIAGNOSTIC SYSTEMS, INC.——
3259CAVALRY BIOSCIENCES INC——
3260NeuroFx, Inc.——
3261Tessa Therapeutics——
3262Oblenio Bio——
3263Aplexis, Inc.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 2 granted of 3

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.